SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates
SIOUX FALLS, S.D., Nov. 14, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today reported financial results for the third quarter ended October 31, 2023, and provided a company update.
- “The third quarter of 2023 was a pivotal growth point for SAB as we advance SAB-142, our T1D immunotherapy.
- The full proceeds, when funded, are expected to fund the company through 2026 and through topline Phase 2 results.
- Russell P. Beyer, former EVP and Chief Financial Officer, departed the Company effective October 27, 2023.
- The decrease was primarily due to discretionary cost reduction measures and increased efficiencies as we continue to mature as a publicly traded company.